2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone has been researched along with Acute Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Budman, DR; Ferrari, A; Schulman, P; Van Echo, DA; Wiernik, PH | 1 |
1 other study(ies) available for 2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone and Acute Disease
| Article | Year |
|---|---|
A phase I trial of aziridinylbenzoquinone (NSC 192986) in patients with previously treated acute leukemia.
Topics: Acute Disease; Adult; Aged; Aziridines; Azirines; Benzoquinones; Cyclohexenes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukemia; Leukocyte Count; Male; Middle Aged; Platelet Count | 1982 |